Akcea’s rare disease drug Waylivra way too pricey for NHS, says NICELess than a week into 2020 and NICE has provisionally ruled against NHS funding for another drug – Share XAkcea’s rare disease drug Waylivra way too pricey for NHS, says NICEhttps://pharmaphorum.com/news-market-access/akceas-rare-disease-drug-waylivra-way-too-pricey-for-nhs-says-nice/
Alnylam to file rare kidney disease drug after trial winAfter years where RNA interference research was in the doldrums, Alnylam is on a roll and is preparing Share XAlnylam to file rare kidney disease drug after trial winhttps://pharmaphorum.com/news/alnylam-to-file-rare-kidney-disease-drug-after-phase-3-win/
Pfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drugPfizer has signed a deal with Ionis’ affiliate Akcea Therapeutics, to develop a potential blockbuster antisense therapy to Share XPfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drughttps://pharmaphorum.com/news/pfizer-inks-deal-with-ionis-and-akcea-for-potential-blockbuster-diabetes-and-nash-drug/
Ionis’ FCS drug approved in EU, launch due in GermanyIonis Pharmaceuticals’ RNA-targeted drug Waylivra has been conditionally approved in Europe for the devastating ultra-rare disease Familial Chylomicronemia Share XIonis’ FCS drug approved in EU, launch due in Germanyhttps://pharmaphorum.com/news/ionis-fcs-drug-approved-in-eu-launch-due-in-germany/
NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayNICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in Share XNICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayhttps://pharmaphorum.com/news/nice-backs-akceas-tegsedi-pipping-alnylam-to-hattr-okay/
Akcea/Ionis’ rare disease drug Waylivra set for EU market after rejection in USEuropean regulators have recommended a licence for Akcea and Ionis’ ultra-rare disease drug Waylivra, a therapy that the Share XAkcea/Ionis’ rare disease drug Waylivra set for EU market after rejection in UShttps://pharmaphorum.com/news/akcea-ionis-rare-disease-drug-waylivra-set-for-eu-market-after-rejection-in-us/
Novartis licenses lipoprotein-lowering CVD drugExcited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment Share XNovartis licenses lipoprotein-lowering CVD drughttps://pharmaphorum.com/news/novartis-licenses-lipoprotein-lowering-cvd-drug/
Eyeing Novartis deal, Akcea trumpets lipoprotein drug dataIonis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with Share XEyeing Novartis deal, Akcea trumpets lipoprotein drug datahttps://pharmaphorum.com/news/eyeing-novartis-deal-akcea-trumpets-lipoprotein-drug-data/
